Historical data shows that a consistent $500 monthly investment into Carisma Therapeutics, Inc. (CARM) starting in 2020 would have turned a total investment of $49K into $116K today. This represents a total return of 138.8% over the 6-year period, compounding through dividend reinvestment and market growth.
The Impact of Dividend Reinvestment (DRIP)
Carisma Therapeutics, Inc. does not currently pay a notable dividend. For growth-focused stocks like CARM, dollar cost averaging relies entirely on price appreciation. Over the 6-year period, the strategy successfully captured the stock's price movements, resulting in a final portfolio value of $116K without the need for dividend reinvestment.
CARM vs. S&P 500 (SPY) Benchmark
When comparing this dollar cost averaging strategy against a broad market index,CARM outperformed the S&P 500 ETF (SPY). The same $500 monthly contributions into SPY would have grown to $87K, compared to CARM's $116K.